trending Market Intelligence /marketintelligence/en/news-insights/trending/EG6oOLZlb_6EXg__1xeYug2 content esgSubNav
In This List

HVIVO director resigns

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


HVIVO director resigns

HVIVO PLC said Graham Yeatman stopped being a director of the company, effective Dec. 31, 2018.

As previously announced in September 2018, Yeatman also stepped down as hVIVO's chief financial and business officer.

He joined the company's board as finance director in 2011 and was promoted to the chief financial and business officer post in 2015.

The company has named Shelley Fraser to replace Yeatman as finance director.

London-based hVIVO is developing a human-based clinical trial platform for drug and vaccine development in respiratory and infectious diseases.